1,556 reports of this reaction
4.2% of all AMIKACIN reports
#4 most reported adverse reaction
DYSPNOEA is the #4 most commonly reported adverse reaction for AMIKACIN, manufactured by Insmed Incorporated. There are 1,556 FDA adverse event reports linking AMIKACIN to DYSPNOEA. This represents approximately 4.2% of all 37,285 adverse event reports for this drug.
Patients taking AMIKACIN who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among AMIKACIN users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for AMIKACIN:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,556 FDA reports for AMIKACIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 4.2% of all adverse event reports for AMIKACIN, making it a notable side effect.
If you experience dyspnoea while taking AMIKACIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.